tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

DE:2GH Stock Latest News

Merus Announces Promising Phase 2 Trial Results
Company AnnouncementsMerus Announces Promising Phase 2 Trial Results
2d ago
8K
MRUS
Biohaven provides oncology program update
PremiumThe Fly
Biohaven provides oncology program update
3d ago
BHVN
MRUS
Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz
PremiumThe Fly
Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz
8d ago
X
BAH
Merus price target raised to $110 from $96 at BMO Capital
PremiumThe Fly
Merus price target raised to $110 from $96 at BMO Capital
8d ago
MRUS
Merus price target raised to $92 from $70 at BofA
PremiumThe Fly
Merus price target raised to $92 from $70 at BofA
8d ago
MRUS
Promising Potential of Merus’s Petosemtamab: A Buy Rating Backed by Impressive Efficacy and Safety
PremiumRatingsPromising Potential of Merus’s Petosemtamab: A Buy Rating Backed by Impressive Efficacy and Safety
8d ago
MRUS
Merus’s Peto+Pembro Shows Promising Potential in HNSCC with High Survival Rates and Increased Price Target
Premium
Ratings
Merus’s Peto+Pembro Shows Promising Potential in HNSCC with High Survival Rates and Increased Price Target
8d ago
MRUS
Merus’s Promising Oncology Advancements Justify Buy Rating Amidst Strong Clinical Results
Premium
Ratings
Merus’s Promising Oncology Advancements Justify Buy Rating Amidst Strong Clinical Results
8d ago
MRUS
Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
PremiumThe Fly
Closing Bell Movers: Deckers falls 15% on weak guidance; Nuclear names rally
8d ago
NNE
SMR
Merus updates on Petosemtamab+Pembrolizumab data in HNSCC
PremiumThe Fly
Merus updates on Petosemtamab+Pembrolizumab data in HNSCC
9d ago
MRUS
Merus Shareholders Approve Key Proposals at AGM
PremiumCompany Announcements
Merus Shareholders Approve Key Proposals at AGM
9d ago
8K
MRUS
Merus’s HNSCC Program Potential Drives Buy Rating Amid Market Opportunities and Challenges
PremiumRatings
Merus’s HNSCC Program Potential Drives Buy Rating Amid Market Opportunities and Challenges
10d ago
MRUS
Promising Developments in Cancer Treatment Drive Buy Rating for Merus with $67 Price Target
PremiumRatingsPromising Developments in Cancer Treatment Drive Buy Rating for Merus with $67 Price Target
10d ago
MRUS
Merus’s Market Potential Bolstered by Anticipated Data Release for Peto
Premium
Ratings
Merus’s Market Potential Bolstered by Anticipated Data Release for Peto
12d ago
MRUS
Promising Outlook for Merus’s Petosemtamab in HNSCC Treatment Drives Buy Rating
Premium
Ratings
Promising Outlook for Merus’s Petosemtamab in HNSCC Treatment Drives Buy Rating
12d ago
MRUS
Merus announces publication on mechanism of action of petosemtamab
PremiumThe Fly
Merus announces publication on mechanism of action of petosemtamab
16d ago
MRUS
Merus’s Superior Clinical Execution and Strategic Advancements Drive Buy Rating
PremiumRatings
Merus’s Superior Clinical Execution and Strategic Advancements Drive Buy Rating
17d ago
MRUS
Merus’s Promising ASCO Presentation: A Catalyst for Growth with Buy Rating from Matt Phipps
PremiumRatings
Merus’s Promising ASCO Presentation: A Catalyst for Growth with Buy Rating from Matt Phipps
18d ago
MRUS
Merus NV (MRUS) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Merus NV (MRUS) Q1 Earnings Cheat Sheet
20d ago
MRUS
Merus price target lowered to $89 from $91 at Wells Fargo
PremiumThe FlyMerus price target lowered to $89 from $91 at Wells Fargo
23d ago
MRUS
Merus’s Promising Clinical Data and Market Positioning Drive Buy Rating
Premium
Ratings
Merus’s Promising Clinical Data and Market Positioning Drive Buy Rating
23d ago
MRUS
Promising Outlook for Merus: Buy Rating Backed by Petosemtamab’s Potential and Strong Financial Position
Premium
Ratings
Promising Outlook for Merus: Buy Rating Backed by Petosemtamab’s Potential and Strong Financial Position
23d ago
MRUS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >